Clinical Trial Update: A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)

View source ↗

Summary

A postmarketing surveillance study evaluated whether a variable titration regimen at the start of Rebif treatment improves patient compliance in Relapsing-remit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED